Table 4.
Study group | Unadjusted risk (%) | Risk after risk score adjustment (%) | Risk after propensity score adjustment (%) |
---|---|---|---|
No prophylaxis (n=58) | 20.7 | 25.7 | 23.1 |
PD stent alone (n=249) | 16.1 | 15.3 | 15.7 |
Indomethacin and PD stent (n=247) | 9.7 | 9.4 | 9.5 |
Indomethacin alone (n=48) | 6.3 | 7.8 | 7.1 |
ERCP, endoscopic retrograde cholangiopancreatography; PD, pancreatic duct.